INB-400 经过设计,可以抵抗烷基化化疗,使其能够与目前的标准治疗 TMZ 结合使用,以放大免疫信号,最大限度地杀死肿瘤,并消除癌细胞。有关该 2期研究 (NCT05664243) 的更多信息可在http://www.clinicaltrials.gov上找到。 关于INB-400INB-400 是 IN8bio 的 DeltEx 化疗耐药自体耐药免疫疗法(DRI)。INB-400 于...
被引量: 0发表: 2024年 Current and future of immunotherapy for thyroid cancer based on bibliometrics and clinical trials Background: Thyroid cancer is a leading endocrine malignancy, with anaplastic and medullary subtypes posing treatment challenges. Existing therapies have l... K Wang,Y Zhang,Y Xi...
Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University; Centre for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, Tübingen, Germany, Tübingen, GermanyLouisa Von Baumgarten...
2. Glioblastoma treatment with irradiation and olaptesed pegol (NOX-A12) in MGMT unmethylated patients (GLORIA). ClinicalTrials.gov. Updated June 22, 2023. Accessed November 21, 2023. https://clinicaltrials.gov/study/NCT04121455Recent Videos Hijioka Discusses STARTER-NET: Everolimus Plus Lanreotide...
August 14, 2024 By Roman Fabbricatore Fact checked by Gina Mauro News ArticleNeoadjuvant/adjuvant sacituzumab govitecan showed encouraging intratumoral concentrations in patients with brain metastases as well as glioblastoma. Neoadjuvant/adjuvant sacituzumab govitecan showed encouraging intratumoral...
3. A trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma (GBM AGILE). ClinicalTrials.gov. Updated June 10, 2024. Accessed July 10, 2024. 4. US FDA awards fast track designation (FTD) to paxalisib for glioblastoma. News release.Kazia TherapeuticsLimited. August 20...
Shuttle Pharmaceuticals receives FDA approval to proceed with phase II clinical trial of ropidoxuridine for treatment of patients with glioblastoma. News release. Shuttle Pharmaceuticals Holdings, Inc. January 8, 2024. Accessed January 8, 2024.http://tinyurl.com/yh5dvmj8 ...
Jimenez, C. et al. Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials. European Journal of Endocrinology 159, 517–523 (2008). ArticleCASGoogle Scholar Nobels, F. R. E. et al. Long-term treatment with the dopamine agonist quinagolide...
clinical trials, two dendritic cell (DC)-based vaccines, sipuleucel-T (Provenge) and DCVax-Brain, are approved in the USA and Switzerland, respectively... M Okamoto - Springer Japan 被引量: 0发表: 2016年 OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024 Glioblastoma...
Upfront temozolomide and bevacizumab was well tolerated, but synergistic chemotherapy or growth factor inhibitors need to be added to produce meaningful clinical benefit, particularly for unresectable or multifocal GBM. 展开 DOI: 10.1200/jco.2009.27.15_suppl.e13025 被引量: 160 ...